Emergence of Saccharomyces cerevisiae as a human pathogen Implications for biotechnology

Enzyme and Microbial Technology

Volumn 25, Issue 7, 1999, Pages 551-557

  Murphy, Alan ^a   Kavanagh, Kevin ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Biotechnology; Emerging pathogen; Saccharomyces

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; BORIC ACID; CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; PROTEINASE; RESTRICTION ENDONUCLEASE;

BIOTECHNOLOGY; BONE MARROW TRANSPLANTATION; CANDIDA; CELL STRUCTURE; DRUG RESISTANCE; ENZYME ACTIVITY; FUNGUS IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; MOUTH INFECTION; MYCOSIS; NEPHROTOXICITY; PATHOGENICITY; PHARYNGITIS; PHENOTYPE; REVIEW; RISK FACTOR; SACCHAROMYCES CEREVISIAE; THERMOSTABILITY; VAGINITIS; VIRULENCE;

SACCHAROMYCES CEREVISIAE;

EID: 0032885847     PISSN: 01410229     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0141-0229(99)00086-1     Document Type: Review

References (48)

1. Schreuder M.P., Mooren T.A., Toschka H.Y., Verrips C.T., Klis F.M. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol. 14:1996;115-120.
2. Shouval D., Ilan Y., Adler R., Deepen R., Panet A., Even-Chen Z., Gorecki M., Gerlich W.H. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 12:1994;1453-1459.
3. Tur E. Classic Kaposi's sarcoma low dose interferon-alpha treatment . Dermatology. 197:1998;37-42.
4. Krown S.E. Interferon-alpha evolving therapy for AIDS-associated Kaposi's sarcoma . J Interfer Cytol Res. 18:1998;209-214.
5. King C.L., Gallin J.L., Malech H.L., Abramson S.L., Nutman T.B. Regulation of immunoglobulin production in hyperimmunoglobulin C recurrent infection syndrome by interferon gamma. Proc Natl Acad Sci. 86:1989;10085-10089.
6. Baehner B.L. Chronic granulomatous disease of childhood clinical, pathological, biochemical and molecular genetics aspects of the disease . Pediar Pathol. 10:1990;143-153.
7. de Hoog G.S. Risk assessment of fungi reported from humans and animals. Mycoses. 39:1996;407-417.
8. Byron J.K., Clemons K.V., McCusker J.H., Davis R.W., Stevens D.A. Pathogenicity of Saccharomyces cerevisiae in complement factor five-derived mice. Infect Immun. 63:1995;478-485.
9. Sobel J.D., Vazquez J., Lynch M., Meriwether C., Zervos M.J. Vaginitis due to Saccharomyces cerevisiae epidemiology, clinical aspects and therapy . Clin Infect Dis. 16:1993;93-99.
10. Smith D.L. Brewer's yeast as a cause of infection. Clin Infect Dis. 22:1996;201.
11. Odds FC, editor. Candidosis of the genitalia. In: Candida and candidosis. 2 edn. London: Baliere Tindall, 1988. p. 124-35.
12. Nyirjesky P., Vazquez J.A., Ufberg D.D., Sobel J.D., Boikov D.A., Buckley H.R. Saccharomyces cerevisiae vaginitis transmission from yeast used in baking . Obstet Gynecol. 86:1995;326-329.
13. McCullough M.J., Clemons K.V., McCusker J.N., Stevens D.A. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval). J Clin Microbiol. 36:1998;2613-2617.
14. Agatensi L., Farnchi F., Mondello F., Bevilacqua R.L., Ceddia T., De Bernardis F., Cassone A. Vaginopathic and proteolytic Candida species in outpatients attending a gynecology clinic. J Clin Pathol. 44:1991;826-830.
15. Clemons K.V., Park P., McCusker J.H., McCullough M.J., Davis R.W., Stevens D.A. Application of DNA typing methods and genetic analysis to epidemiology and taxonomy of Saccharomyces. J Clin Microbiol. 35:1997;1822-1828.
16. Tawfik O.W., Papasian C.J., Dixon A.Y., Potter L.M. Saccharomyces cerevisiae pneumonia in a patient with acquired immune deficiency syndrome. J Clin Microbiol. 27:1989;1689-1691.
17. Auscott J.N., Fayen J., Grossnicklas H., Morrissey A., Ledermann M.M., Salatta R. Invasive infection with Saccharomyces cerevisiae report of three cases and review . Rev Infect Dis. 12:1990;406-411.
18. Cairoli R., Marenco P., Perego R., de Cataldo F. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transpl. 15:1995;785-786.
19. Oriol A., Ribera J.M., Arnal J., Milla F., Batlle M., Feliu E. Saccharomyces cerevisiae septicemia in a patient with myelodysplaastic syndrome. Am J Hematol. 43:1993;325-326.
20. Eschette M.L., West B.C. Saccharomyces cerevisiae septicaemia. Arch Intern Med. 140:1980;1539.
21. Dougherty S.H., Simmons R.L. Postoperative peritonitis caused by Saccharomyces cerevisiae. Arch Surg. 117:1982;248-249.
22. Giaffer M.H., Clark A., Holdsworth C.D. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. GUT. 33:1992;1071-1075.
23. Eng R.H.K., Drehmel R., Smith S.M., Goldstein E.J.C. Saccharomyces cerevisiae infections in man. J Med Vet Mycol. 22:1984;403-407.
24. Jensen D., Smith D. Fever of unknown origin secondary to brewer's yeast ingestion. Arch Intern Med. 136:1976;323-325.
25. McFarland L.V. Saccharomyces cerevisiae is not Saccharomyces boulardii. Clin Infect Dis. 22:1996;200-201.
26. McCusker J.H., Clemons K.V., Stevens D.A., Davis R.W. Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics. 136:1994;1261-1269.
27. Kaminishi H., Miyaguchi H., Tamaki T., Suenaga N., Hisamatsu M., Mihashi I., Matsumoto H., Maeda H., Hagihara Y. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun. 63:1995;984-988.
28. McCusker J.H., Clemons K.V., Stevens D.A., Davis R.W. Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42°C and form pseudohyphae. Infect Immun. 62:1994;5447-5455.
29. Clemons K.V., McCusker J.H., Davis R.W., Stevens D.A. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J Infect Dis. 169:1994;859-867.
30. Soll D. High frequency switching in Candida albicans. Clin Microbiol Rev. 5:1992;183-203.
31. Soll D. Gene regulation during high frequency switching in C. albicans. Microbiology. 143:1997;279-288.
32. Clemons K.V., Hanson L.C., Stevens D.A. Colony phenotype switching in clinical and non-clinical isolates of Saccharomyces cerevisiae. J Med Vet Mycol. 34:1996;259-264.
33. Hodgetts S., Matthews R., Morrissey G., Mitsutake K., Piper P., Burnie J. Over expression of Saccharomyces cerevisiae hsp90 enhances virulence in mice. FEMS Immunol. Med. Microbiol. 16:1996;229-234.
34. Janoff A.S., Perkins W.R., Saletan S.L., Swenson C.E. Amphotericin B lipid complex a molecular rationale for the attenuation of amphotericin B related toxicities . J Liposome Res. 3:1993;451-471.
35. Metha J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leuk Res. 21:1997;183-187.
36. Herbrecht R. Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 16:1997;74-80.
37. Orozco A.S., Higginbotham L.M., Hitchcock C.A., Parkinson T., Falconer D., Ibrahim A.S., Ghannoum M.A., Filler S.G. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 42:1998;2645-2649.
38. Anaissie E.J., Mattiuzzi G.N., Miller C.B., Noskin G.A., Gurwith M.J., Mamelok R.D., Pietrelli L.A. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother. 43:1998;606-611.
39. Noskin G.A., Pietrelli L., Coffey G., Gurwith M., Liang L. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis. 26:1998;461-467.
40. Oppenheim B.A., Herbrecht R., Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis. 21:1995;1145-1153.
41. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B recent progress and future directions . Clin Infect Dis. 2:1996;133-144.
42. Espinel-Ingroff A. In vitro activity of the new triazole Voriconazole (UK-109-496) against opportunistic filamentous and dimorphic fungi and common emerging yeast pathogens. J Clin Microbiol. 36:1998;198-202.
43. Tiballi R.N., Spiegel J.E., Zarins L.T., Kauffmann C.A. Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. Diagn Microbiol Infect Dis. 23:1995;135-140.
44. Pfaller M., Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis. 11:1992;287-291.
45. Samaranayake Y.H., Samaranayake L.P. Candida krusei biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen . J Med Microbiol. 41:1994;295-310.
46. Odds F.C. Epidemiological shifts in opportunistic and nosocomial Candida infections mycological aspects . Int J Antimicrobial Agents. 6:1996;141-144.
47. Hallstrom T.C., Moye-Rowley W.S. Divergent transcriptional control of multidrug resistance genes in Saccharomyces cerevisiae. J Biol Chem. 273:1998;2098-2104.
48. Walker GM, editor. Yeast growth. In: Yeast physiology and biotechnology. London: Wiley, 1998. p. 101-83.